{"id":1018279,"date":"2026-11-06T07:04:24","date_gmt":"2026-11-06T12:04:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/"},"modified":"2026-11-06T07:04:24","modified_gmt":"2026-11-06T12:04:24","slug":"eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/","title":{"rendered":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WATERTOWN, Mass., Nov.  06, 2026  (GLOBE NEWSWIRE) &#8212; EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Guggenheim 3<\/strong><br \/>\n          <sup><br \/>\n            <strong>rd<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Healthcare Innovation Conference <\/strong><br \/>\n          <br \/>Forum: Fireside Chat<br \/>Date: November 9, 2026<br \/>Time: 2:30 pm EST<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Stifel 2026 Healthcare Conference<\/strong><br \/>\n          <br \/>Forum: Fireside Chat<br \/>Date: November 10, 2026<br \/>Time: 1:20 pm EST<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Jefferies 2026 Global Healthcare Conference\u00a0in London<\/strong><br \/>\n          <br \/>Forum: Fireside Chat<br \/>Date: November 16, 2026<br \/>Time: 3:00 pm GMT<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>UBS Global Biopharma Conference\u00a02026<\/strong><br \/>\n          <br \/>Forum: Fireside Chat<br \/>Date: November 17, 2026<br \/>Time: 8:40 am GMT<\/p>\n<\/li>\n<\/ul>\n<p>A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors section of the Company website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nVRp14HUcLqZssWPIpdTYOOLfaeBF2I5hL9o1yzCYzdTKjYJkrK61t_ySmLu76A6ISgGOKTqDjqmK0d5goiPn-ojArJVvpPieHE0Z5t0c9o=\" rel=\"nofollow\" target=\"_blank\">www.eyepoint.bio<\/a>.<\/p>\n<p>\n        <strong>Scientific Meetings<\/strong>\n      <\/p>\n<p>EyePoint will be participating at the following scientific meetings:<\/p>\n<p>\n        <strong>Eyenovate at FLORetina<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Presentation: <\/strong>LUCIA Pivotal Phase 3 Trial Results: Primary Efficacy and Safety of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD<br \/><strong>Presenter: <\/strong>Anat Loewenstein, M.D. <br \/><strong>Date &amp; Time (Session): <\/strong>December 3, 2026 | 9:40 AM CET (Session 2 \u2013 The Hunt for a Durable wAMD Treatment)<br \/><strong>Panel Discussion: <\/strong>The Near and Far Future of Wet AMD Treatment: Durability, New Treatment Pathways, Combines Therapies with Ramiro Ribeiro, M.D., Ph.D.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Presentation: <\/strong>Significance of IL-6 Inhibition in DME and Update on Phase 3 COMO\/CAPRI Trials<br \/><strong>Presenter: <\/strong>Ramiro Ribeiro, M.D., Ph.D.<br \/><strong>Date &amp; Time (Session): <\/strong>December 3, 2026 | 11:15 AM CET (Session 3 \u2013 Vascular\/Diabetic Retinal Diseases: New Associations and Treatments)<br \/><strong>Panel Discussion:<\/strong> From Controlling Neovascularization to Restoring Vascular Function with Ramiro Ribeiro, M.D., Ph.D.<\/li>\n<\/ul>\n<p>\n        <strong>FLORetina-ICOOR 2026 Congress<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Presentation: <\/strong>EYP-1901 in the Management of Macular Disease <br \/><strong>Presenter: <\/strong>Tarek S. Hassan, M.D. <br \/><strong>Date &amp; Time (Session): <\/strong>December 4, 2026 | 3:45 PM CET (ASRS Session \u2013 US Retinal Therapies, Update from ASRS: Durable and Sustained Treatments for Neovascular AMD)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Presentation: <\/strong>Bioerodible EYP-1901 (vorolanib intravitreal insert) for Diabetic Macular Edema: Overview of COMO and CAPRI Pivotal Phase 3 Trials<br \/><strong>Presenter: <\/strong>David S. Boyer, M.D. <br \/><strong>Date &amp; Time (Session): <\/strong>December 4, 2026 | 4:30 PM CET (DME &amp; Diabetic Retinopathy \u2013 Retina Futura Spotlight: Medical Treatment)<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Presentation: <\/strong>LUCIA Pivotal Phase 3 Trial Efficacy and Safety Results of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD<br \/><strong>Presenter: <\/strong>Charles C. Wykoff, M.D. <br \/><strong>Date &amp; Time (Session): <\/strong>December 5, 2026 | 12:00 PM CET (Neovascular AMD Treatment \u2013 Retina Futura Spotlight)<\/p>\n<\/li>\n<\/ul>\n<p>Presentations from these meetings will be available in the Scientific Publications section of the Company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nVRp14HUcLqZssWPIpdTYABOVSDi6ZL6PQmmzayomwn0WWaQ-Wra9ou-r9KsKcH_NJloHh2raWRXJ3kJl84gq6omtU31YQ2T5IgHHSPn4D8=\" rel=\"nofollow\" target=\"_blank\">www.eyepoint.bio<\/a> after each event.<\/p>\n<p>\n        <strong>About EyePoint<\/strong>\n      <\/p>\n<p>EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company\u2019s lead product candidate, DURAVYU\u2122, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint\u2019s proprietary bioerodible Durasert E\u2122 sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).<\/p>\n<p>The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.<\/p>\n<p>EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.<\/p>\n<p>Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.<\/p>\n<p>\n        <em>DURAVYU<\/em><br \/>\n        <sup><br \/>\n          <em>\u2122<\/em><br \/>\n        <\/sup><br \/>\n        <em> has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.<\/em>\n      <\/p>\n<p>\n        <strong>Investors &amp; Media:<\/strong>\n      <\/p>\n<p>Robin Garner<br \/>VP, Corporate Communications &amp; Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VqLWaEkQd3YbgKQEN_thDImIGsRdicCIu88Lq5GucdGCE65CNuLD1QJUE-Kvi5w2-agoQVB9Ze1nxb5e80N_YiOIY9d8VH1cX8fF7FrqQX8=\" rel=\"nofollow\" target=\"_blank\">ir@eyepoint.bio<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjdmYTg3YWEtZmZlYi00MDQ1LWE4YzQtMGViNDgyM2VkM2JjLTEwMTczOTAtMjAyNi0xMS0wNi1lbg==\/tiny\/EyePoint-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) &#8212; EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: November 9, 2026Time: 2:30 pm EST Stifel 2026 Healthcare Conference Forum: Fireside ChatDate: November 10, 2026Time: 1:20 pm EST Jefferies 2026 Global Healthcare Conference\u00a0in London Forum: Fireside ChatDate: November 16, 2026Time: 3:00 pm GMT UBS Global Biopharma Conference\u00a02026 Forum: Fireside ChatDate: November 17, 2026Time: 8:40 am GMT A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1018279","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) &#8212; EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: November 9, 2026Time: 2:30 pm EST Stifel 2026 Healthcare Conference Forum: Fireside ChatDate: November 10, 2026Time: 1:20 pm EST Jefferies 2026 Global Healthcare Conference\u00a0in London Forum: Fireside ChatDate: November 16, 2026Time: 3:00 pm GMT UBS Global Biopharma Conference\u00a02026 Forum: Fireside ChatDate: November 17, 2026Time: 8:40 am GMT A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors &hellip; Continue reading &quot;EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T12:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings\",\"datePublished\":\"2026-11-06T12:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/\"},\"wordCount\":601,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/\",\"name\":\"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\",\"datePublished\":\"2026-11-06T12:04:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk","og_description":"WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) &#8212; EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Forum: Fireside ChatDate: November 9, 2026Time: 2:30 pm EST Stifel 2026 Healthcare Conference Forum: Fireside ChatDate: November 10, 2026Time: 1:20 pm EST Jefferies 2026 Global Healthcare Conference\u00a0in London Forum: Fireside ChatDate: November 16, 2026Time: 3:00 pm GMT UBS Global Biopharma Conference\u00a02026 Forum: Fireside ChatDate: November 17, 2026Time: 8:40 am GMT A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors &hellip; Continue reading \"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-06T12:04:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings","datePublished":"2026-11-06T12:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/"},"wordCount":601,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/","name":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=","datePublished":"2026-11-06T12:04:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MjAwMiM3OTUwNDMwIzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1018279"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1018279\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1018279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1018279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1018279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}